Article Text

Download PDFPDF

Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case–control study protocol
  1. Zsolt Szakács1,2,3,
  2. Beáta Csiszár1,4,
  3. Péter Kenyeres1,4,
  4. Patrícia Sarlós1,5,
  5. Bálint Erőss3,5,
  6. Alizadeh Hussain1,6,
  7. Ágnes Nagy6,
  8. Balázs Kőszegi7,
  9. Ibolya Veczák5,
  10. Nelli Farkas8,
  11. Emőke Bódis3,
  12. Katalin Márta1,3,
  13. Andrea Szentesi3,
  14. Margit Tőkés-Füzesi9,
  15. Tímea Berki10,
  16. Áron Vincze1,2,5,
  17. Kálmán Tóth1,4,
  18. Péter Hegyi1,2,3,
  19. Judit Bajor2,5
  1. 1 János Szentágothai Research Center, University of Pécs, Pécs, Hungary
  2. 2 Clinical Medicine Doctoral School, University of Szeged, Szeged, Hungary
  3. 3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
  4. 4 Division of Cardiology and Angiology, First Department of Medicine, University of Pécs, Pécs, Hungary
  5. 5 Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary
  6. 6 Division of Hematology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary
  7. 7 Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, Pécs, Hungary
  8. 8 Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary
  9. 9 Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary
  10. 10 Department of Immunology and Biotechnology, Medical School, University of Pécs, Pécs, Hungary
  1. Correspondence to Dr Péter Hegyi; p.hegyi{at}tm-centre.org

Footnotes

  • PH and JB contributed equally.

  • Contributors JB is the Principal Investigator. ZS is the Trial Co-ordinator. ZS, PH, JB, ÁV and KT conceptualised the study, drafted and revised this manuscript. NF and EB planned and drafted the statistical analysis. PS, JB, BE and ÁV provided us with special expertise in the management of coeliac disease and inflammatory bowel patients. BC and PK are performing the haemorheological measurements and interpreting the results. AH, ÁN, TB and MT-F provided us with special expertise in hemostatic and immunological measurements. BK is contributing significantly to the biochemical analyses. IV planned and is carrying out the dietary assessment of the coeliac patients. KM, AS, ZS and PH are responsible for data management, administrative co-ordination and biological sampling; they drafted and revised the manuscript. All the authors have read and approved the final manuscript.

  • Funding The project is non-industry-funded. Study and centre costs are covered by the University of Pécs Medical School, by a Momentum Grant from the Hungarian Academy of Sciences (LP2014-10/2014), by a Highly Cited Publication Grant (KH 125678) from the National Research Development and Innovation Office, by GINOP 2.3.2-15-2016-00048 Stay Alive, EFOP-3.6.2-16-2017-0006, and EFOP-3.6.3-VEKOP-16-2017-00009; and by the Translational Medicine Foundation. In addition, this project is supported by the ÚNKP-17-3-II and ÚNKP-18-3-I New National Excellence Programme, Ministry of Human Capacities. Funders have no influence on preparations, course, interpretation, or publication of results.

  • Competing interests None declared.

  • Ethics approval The study was approved by the Regional and Local Research Ethics Committee, University of Pécs (Ref No 6917).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

View Full Text

Statistics from Altmetric.com

Strengths and limitations of this study

  • Immune-mediated bowel diseases are associated with an increased risk of arterial and venous thrombosis, but specific haemorheological and haemostatic alterations are understudied in coeliac disease (CeD) and incomplete in inflammatory bowel disease (IBD).

  • This case–control study prospectively recruits newly diagnosed and followed-up cases of CeD and IBD with age-matched and sex-matched controls (the allocation ratio will be 1:1:1, respectively) to investigate clinical and laboratory alterations predisposing to thrombosis.

  • Laboratory tests include the measurement of haemorheological (ie, erythrocyte aggregation and deformability, plasma and whole blood viscosity), haemostatic parameters (eg, levels of fibrinogen, prothrombin time, protein C, protein S and antithrombin) and immunological indicators (eg, coeliac-specific serology and antiphospholipid antibodies).

  • Patients will be divided by disease activity into active and inactive.

  • Results should be interpreted with caution due to the single-centre nature and case–control design of the study.

Introduction

Immune-mediated disorders may affect 5%–7% of the population.1 These disorders frequently share pathways in pathogenesis as well as organ manifestations. Coeliac disease (CeD) and inflammatory bowel disease (IBD) are systemic disorders, primarily affecting the intestines.2 They impose a significant burden of complications and concomitant diseases on patients during the disease course.

CeD is a chronic, immune-mediated disorder, which develops on gluten ingestion in genetically susceptible individuals.3 Global prevalence of CeD is around 1% with geographical differences ranging from 0.14% up to 5.7%.3 The clinical presentation can be divided into classic, non-classic and asymptomatic forms.4 Diagnosing asymptomatic and atypical cases is challenging but important, because the disease course of these cases may be alike.5

IBD—clinically classified as Crohn’s disease or ulcerative colitis—is a chronic, relapsing disorder, which develops as a result of the interaction between environmental and genetic factors, leading to immunological responses and inflammation in the gastrointestinal tract.6 IBD is a less frequent entity than CeD: the increasing prevalence of ulcerative colitis and Crohn’s disease may reach 0.5% and 0.3% in Europe, respectively.7 8

Immune-mediated disorders may be associated with haemorheological9–11 and haemostatic changes,12–14 thereby contributing to an increased risk of thrombotic events.15 This increased risk is manifested in CeD16 and IBD.17 Mechanisms of thrombophilia in immune-mediated disorders are complex, and acquired factors seem important.18 An altered haemorheological profile as well as the altered levels or function of pro-coagulant and anticoagulant proteins, altered activity of clotting factors contribute to the development of arterial and venous thrombotic events.19–23

Clinical presentation of CeD-associated hypercoagulability includes a wide variety of thrombosis at venous sites, pulmonary embolism, atheroembolism (stroke) and obstetric complications.24 25 A single retrospective publication examined haemostatic alterations in a small cohort of patients: sporadic cases of protein C and protein S deficiency (due to vitamin K malabsorption), hyperhomocysteinaemia, and antiphospholipid antibodies were identified.26 No studies have assessed the haemorheological changes in CeD. The multifactorial aetiology of thrombosis may embrace the interplay of malabsorption (vitamin and mineral deficiencies, eg, vitamin B12 and K deficiency), thrombophilic autoantibodies [anti-tissue transglutaminase (tTG) and antiphospholipid antibodies], hyperhomocysteinaemia, endothelial dysfunction, accelerated atherosclerosis, thrombocytosis and thrombocyte dysfunction, hyperviscosity, and genetics.24 26–31 Immune-mediated comorbidities (‘autoimmune traits’), such as antiphospholipid syndrome, may contribute to the elevated thrombotic risk as well.29 In addition, ingestion of trace amounts of gluten may maintain a continuous pro-inflammatory response.32

IBD is associated with venous thrombosis and pulmonary embolism as well as with the cardiovascular consequences of atherosclerosis, ie, stroke and myocardial infarction.33 34 A significant decline in anticoagulant mechanism is well-established and there are sporadic reports on activity-dependent prothrombotic haemorheological changes.35–38 However, while individual studies have focused on single outcomes of laboratory parameters, none of them have assessed the complete haemorheological profile of patients.39–42 Other risk factors include immobilisation, surgical interventions, glucocorticoid therapy, vitamin deficiencies, hyperhomocysteinaemia and chronic inflammation alone or in conjunction with the factors above.43 44 In the case of IBD, disease activity may be a crucial determinant of thrombotic risk.34

Scope and objectives

No studies have assessed haemorheological and haemostatic parameters within a study to provide an overall view of thrombotic risk. Since our knowledge of haemorheological and haemostatic changes is limited in CeD and IBD, this study aims to carry out a comprehensive evaluation of venous and arterial prothrombotic alterations in these pro-inflammatory diseases in a Hungarian cohort of patients.

  1. Primary objective.

    • To identify a link between prothrombotic haemorheological and haemostatic alterations and two common immune-mediated diseases (CeD and IBD).

  2. Secondary objective.

    • To investigate the effect of disease activity on the haemorheological and haemostatic profiles of CeD and IBD patients.

    • To find an association between the dietary adherence of CeD patients and the haemorheological and haemostatic alterations.

    • To assess the modifying effect of immunosuppressant drugs in IBD on the haemorheological and haemostatic profiles.

Methods and analysis

Design

This is a case–control study with prospective recruitment of CeD and IBD patients with non-CeD, non-IBD control subjects. The study does not change the routine management of subjects included (for the WHO checklist, see table 1). The study protocol was planned in accordance with the Standard Protocol Items: Recommendations for Interventional Trials 2013 Statement.45

Table 1

WHO checklist

Trial organisation and steering committee

The Centre for Translational Medicine at the University of Pécs, which was established to advance medical research in gastroenterology, is the co-ordinator and designer of the HERMES study. The centre is experienced in running investigator-initiated clinical trials.46 A steering committee will be set up to supervise the entire study process. The principal investigator (JB) and the Trial Coordinator (ZS) are responsible for organising patient recruitment, data collection, sample collection, shipping, and storage, biochemical analysis, and the publication of study results.

Population and eligibility

We will include CeD patients, IBD patients, and non-CeD, non-IBD control subjects. Eligibility criteria will be as follows:

  1. Inclusion criteria (applies to all subjects).

    • Blood collection must be indicated with medical conditions.

    • Signed informed consent.

  2. Inclusion criteria (applies to specific cohorts of patients).

    • CeD patients: biopsy-confirmed newly diagnosed or followed patients (with or without adhering to a gluten-free diet) aged ≥18 years; the establishment of a diagnosis should meet the current guidelines (European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPHGAN) and American College of Gastroenterology (ACG)).3 47 48

    • IBD patients: newly diagnosed or followed-up patients (with active or remitting disease) aged ≥18 years (not following a gluten-free diet); the establishment of a diagnosis should meet the current guidelines (European Crohn’s and Colitis Organisation (ECCO).49 50

    • Non-CeD, non-IBD control subjects: individuals aged ≥18 years (not following a gluten-free diet) in whom CeD and IBD can be excluded according to the recent guidelines.3 47–50

  3. Exclusion criteria (applies to all subjects).

    • Chronic conditions.

      • Estimated glomerular filtration rate calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is <60 mL/min/1.73 m2 (CKD3 or more severe kidney failure).

      • Liver cirrhosis in Child–Pugh B–C.

      • Heart failure (New York Heart Association (NYHA) III–IV).

      • Active malignant diseases.

    • Any acute diseases or invasive procedures within 2 weeks of recruitment (eg, systemic infection, surgery, or major trauma).

    • Thrombotic events within 1 year of recruitment.

    • Ongoing oral anticoagulant therapy (vitamin K antagonists) and/or antiplatelet drugs.

    • Confirmed systemic lupus erythematosus.

    • Pregnancy.

    • Patients unable to understand the essentials of the informed consent.

Flow and timing

All subjects at our academic hospital for a planned check-up or referred to the centre for diagnostic purposes will be recruited consecutively. The place of recruitment will be the Division of Gastroenterology, First Department of Medicine, University of Pécs Medical School. This tertiary centre provides professional gastroenterological care for about 300 000 inhabitants in Baranya County, Hungary.

Recruitment of the study population will be managed in two phases (see Target number of patient section), with the expected recruiting period being between May 2018 and May 2019 (covering 1 year). Table 2 shows the timeline of the study. Patients will be provided with an information sheet and must provide written consent before sampling. Informed consent will be obtained by personnel with a medical degree. Participants may withdraw from the study for any reason at any time. Consent forms and other related documents will be accessible at https://tm-centre.org.

Table 2

Schedule for the study

Patients will be monitored by our professional data management team throughout the entire process of data and biological sample collection to ensure perfect adherence to protocol. Written feedback will be provided to patients on the results of the laboratory tests and dietary evaluation. If findings indicate, patients will be referred to their general practitioners or a specialist for further investigation and management.

Measurements

All samples will be collected and questionnaires will be administered within 2 hours after allocation. Actions for each group are defined and listed in table 3.

Table 3

Actions within study

Detailed history (including medications for preceding 3 months) and risk factors of venous and arterial thrombotic events will be covered with a 15 min thrombophilia questionnaire (administered by a person with a medical degree).

The Gastrointestinal Symptoms Rating Scale is a tool designed to assess the severity of gastrointestinal symptoms on a scale of 1–7 (administered by a person with a medical degree).51

Disease activity in IBD will be estimated with either the (modified) Mayo Score52 or Crohn’s Disease Activity Index53 in patients with ulcerative colitis and Crohn’s disease, respectively, while tissue transglutaminase (tTG) levels will be used to measure the activity of CeD. (Scores will be determined by the gastroenterologist enrolling the patient.)

Dietary adherence of CeD patients will be estimated through (1) a dietary interview conducted by a trained dietitian on a scale of 1–10, (2) self-reporting,54 (3) a test measuring knowledge of gluten-free foods, (4) urine gluten-immunogenic peptides (GIP) detection (details in the text) and (5) coeliac-specific serology [tTG and endomysium antibody levels (EMA)].55Patients will be divided into those with good and poor dietary adherence based on the complex assessment of the above-mentioned data.

All laboratory tests will be performed in the same laboratory (University of Pécs, Hungary) from venous blood. Blood samples will be collected in plastic tubes prospectively [2 x BD Vacutainer 10.0 mL (red), 2 x BD Vacutainer 6.0 mL (purple), 1 x BD Vacutainer 3.0 mL (pink), 1 x BD Vacutainer 2.7 mL (blue) and 1 x BD Seditainer 5.0 mL (black) for a total of 42.7 mL blood from each patient (BD, USA)].

We will measure:

  • Routine laboratory parameters: bilirubin, urea, creatinine, cholesterol (total, high-density and low-density lipoproteins), triglyceride, , aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total protein, albumin, immunoglobulins, C reactive protein, vitamin B12, folic acid, homocysteine, blood counts and erythrocyte sedimentation.

  • Immunological indicators: antiphospholipid antibodies (lupus anticoagulant, cardiolipin IgG/IgA/IgM, B2-glycoprotein-I IgG/IgA/IgM, prothrombin IgG/IgA/IgM) and coeliac-specific antibodies (tTG IgA/IgG, EMA IgA).

  • Haemostatic parameters: prothrombin, thrombin time, activated partial thromboplastin time, fibrinogen, antithrombin activity, protein C activity and protein S activity.

  • Haemorheological parameters: erythrocyte aggregation by Myrenne aggregometer (model MA-1, Myrenne GmbH, Roetgen, Germany) and Laser-assisted Optical Rotational Cell Analyzer (LORCA, R&R Mechatronics, Hoorn, The Netherlands); erythrocyte deformability with laser-diffraction ektacytometry with a LORCA; and viscosity of whole blood and plasma by Brookfield DV-III Ultra LV Programmable rotational viscometer (Brookfield Engineering Labs; Middleboro, Mass., USA). The Case Report Form providing data about the measurements is presented in online supplementary material.

Supplementary file 1

Strict adherence will be kept during the haemorheological tests to the guidelines proposed by the International Expert Panel for Standardisation of Haemorheological Methods.56 The fact that equipment for haemorheological measurements is not available in other centres in Hungary and that blood samples must be processed within 2 hours of sampling without freezing restricted our expansion of this project to a multicentre study.

An extra tube will be collected and stored for further haemostatic measurements (eg, clotting factors) if any abnormality of parameters measured is detected.

Midstream urine (at least 100 mL) will be collected in sterile urine sample containers. Samples will be stored at 4°C until transfer to the Biobank at the Institute for Translational Medicine, University of Pécs Medical School, on the day of sampling, where samples will be deep frozen at −80°C. After preparation, urine GIP detection will be performed with Biomedal (Spain) products.

Outcomes

  1. Primary.

    • Haemorheological test results (erythrocyte aggregation and deformability, whole blood and plasma viscosity).

  2. Secondary.

    • Haemostatic test results (antithrombin, protein C, protein S), folic acid, and homocysteine levels.

Target number of patients

This is a two-phase study. In the first phase, we will enrol 50 CeD and 50 IBD patients with 50 age- matched and sex-matched control subjects; the case–control ratio will be 1:1:1, respectively. Then, an interim analysis will be performed to calculate the power for the analyses of the outcomes. If the power exceeds 80%, recruitment will be considered completed; otherwise, recruitment will continue until the desired power is reached.

Patient and public involvement

Before starting recruitment, randomly selected CeD and IBD patients reviewed the questionnaires and the information sheet designed to share details of the study for participants to facilitate better understanding.

Blinding

Blinding of personnel included in the study is presented in table 4.

Table 4

Blinding of personnel included in the study

Data management

A subject identification number will be provided consecutively to every patient after inclusion. Subject identification numbers with sensitive data on patients (including the name, insurance number and date of enrolment) will be stored in a locked file separately from other data. De-identified data will be added to the source documentation stored in locked cabinets. Source documentation will be entered in an electronic case report file (e-CRF). The principal investigators will ensure that the data in an e-CRF are accurate, complete and legible (range checks for data values). E-CRFs will be stored on a secured server at the Institute for Translational Medicine, University of Pécs Medical School. Access to data will be restricted through a password system to personnel involved in data management. A three-level data check will be continuously performed, and final data will be finally approved by the principal investigator to ensure data quality.

To ensure precise data collection, administrative and medical staff members will be invited to participate in training sessions to familiarise them with the study requirements, standardised data recording and biological specimen collection.

The de-identified dataset will be delivered for the purpose of sharing on request.

Statistical analysis

First, descriptive statistics will entail a graphical presentation of data. Continuous variables will be reported as a central tendency with a measure of dispersion, while categorical variables will be reported as absolute and relative frequencies. Then, data will be analysed with Student’s tests, methods of Variance Analysis, and regression models if data are normally distributed; otherwise, non-parametric tests will be introduced. χ2 or Fisher’s tests will be used to analyse categorical variables. Multivariate analysis will be used to take the most important thrombotic factors into account (eg, the use of oral contraceptives and immunosuppressants, previous thrombotic history, smoking, comorbidities). A probability of less than 0.05 indicates a statistically significant difference between groups.

Only patients with a full dataset in their haemorheological and haemostatic profile will be included in the analysis. The following comparisons will be done: CeD versus control, tTG+CeD versus tTG- CeD, CeD with good dietary adherence versus CeD with poor dietary adherence, IBD versus control, active IBD versus remitting IBD and Crohn’s disease versus ulcerative colitis.

An interim analysis is planned after recruiting the target number of the first phase to calculate power. Audits are not necessary due to the case–control design.

Biobank and accessory research

After laboratory analysis, urine and blood (whole blood and plasma, at least 1 mL each) residues will be stored in the Institute for Translational Medicine Biobank at −80°C for future studies (for at least 5 years). Additional samples will not be taken for storage purposes. Containers will be labelled with the subject identification number, and samples will be completely de-identified.

CeD patients will be offered an opportunity to participate in the ‘Monitoring the prevalence, symptoms, complications and family history of CeD and the effect of a gluten-free diet—Coeliac registry’ research project (approved by the Scientific and Research Ethics Committee of the Medical Research Council, Ref. No. 45098-2/2016/EKU).

Protocol amendments and disseminating policy

This protocol is the first version completed on 30 May 2018. If required, the online version will be updated in the ISRCTN registry. Major modifications should be permitted by the Regional and Local Research Ethics Committee.

The trial status is ongoing; recruitment began on 1 May 2018. The expected date of completion is 31 May 2019.

Discussion

Recent guidelines on CeD do not make any recommendations on how to prevent and manage thrombotic events in CeD patients.3 47 Gluten-free diet, which is the only approved treatment of the disease, may reduce or eliminate some thrombotic risk factors (eg, consequences of malabsorption and chronic inflammation) but it is uncertain whether the thrombotic risk completely normalises.57 With respect to malabsorption, intestinal mucosa does not recover in a high fraction of patients despite a long-term strict diet, particularly in those diagnosed in the adulthood.58 Whether CeD patients after a thrombotic event would benefit from a lifelong anticoagulation therapy has remained unclear. The need for thromboprophylaxis under prothrombotic circumstances, such as hospitalisation, pregnancy, or immobilisation should be further investigated.

IBD guidelines recommend that thromboprophylaxis should be considered in all inpatients and outpatients with an active disease.59 60 In addition to disease severity, the choice of treatment influences the thrombotic risk as well.17 A tool of personalised thrombotic risk stratification including objective laboratory markers is awaited.

Our results can contribute to expanding our knowledge on the prothrombotic pathophysiological alteration in CeD and IBD, thereby providing the basis for future research.

Ethics and dissemination

Publication in a high-impact peer-reviewed journal is planned. We will adhere to authorship criteria for manuscripts submitted for publication set by the International Committee of Medical Journal Editors.

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
  55. 55.
  56. 56.
  57. 57.
  58. 58.
  59. 59.
  60. 60.
View Abstract

Footnotes

  • PH and JB contributed equally.

  • Contributors JB is the Principal Investigator. ZS is the Trial Co-ordinator. ZS, PH, JB, ÁV and KT conceptualised the study, drafted and revised this manuscript. NF and EB planned and drafted the statistical analysis. PS, JB, BE and ÁV provided us with special expertise in the management of coeliac disease and inflammatory bowel patients. BC and PK are performing the haemorheological measurements and interpreting the results. AH, ÁN, TB and MT-F provided us with special expertise in hemostatic and immunological measurements. BK is contributing significantly to the biochemical analyses. IV planned and is carrying out the dietary assessment of the coeliac patients. KM, AS, ZS and PH are responsible for data management, administrative co-ordination and biological sampling; they drafted and revised the manuscript. All the authors have read and approved the final manuscript.

  • Funding The project is non-industry-funded. Study and centre costs are covered by the University of Pécs Medical School, by a Momentum Grant from the Hungarian Academy of Sciences (LP2014-10/2014), by a Highly Cited Publication Grant (KH 125678) from the National Research Development and Innovation Office, by GINOP 2.3.2-15-2016-00048 Stay Alive, EFOP-3.6.2-16-2017-0006, and EFOP-3.6.3-VEKOP-16-2017-00009; and by the Translational Medicine Foundation. In addition, this project is supported by the ÚNKP-17-3-II and ÚNKP-18-3-I New National Excellence Programme, Ministry of Human Capacities. Funders have no influence on preparations, course, interpretation, or publication of results.

  • Competing interests None declared.

  • Ethics approval The study was approved by the Regional and Local Research Ethics Committee, University of Pécs (Ref No 6917).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.